{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "CDC_Influenza_vaccines",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 1,
    "new_evidence_found": 0,
    "total_evidence": 1
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "RIV4 (recombinant HA vaccine) contains 45 \u00b5g of HA per 0.5 mL dose, which is 3 times the HA antigen content of standard-dose inactivated influenza vaccines (15 \u00b5g per 0.5 mL dose). Increased HA antigen content has been associated with greater immunogenicity compared with standard-dose vaccines.",
      "relevance_explanation": "This quote explicitly states that RIV4 (Flublok) contains 3 times the HA antigen content of standard-dose flu vaccines and directly links the increased HA content to greater immunogenicity, supporting both parts of the claim."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}